ArticleMovement disorders clinical practice2026
Quantitative Susceptibility Mapping and Iron Deposition in Autopsy-Confirmed Progressive Supranuclear Palsy.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundQuantitative susceptibility mapping (QSM) is a promising neuroimaging biomarker for detecting abnormal iron deposition in progressive supranuclear palsy (PSP); however, the QSM profile and its accuracy in autopsy-confirmed PSP remain unexplored.
objectiveThe aim of the study was to elucidate and validate the QSM profiles in autopsy-confirmed PSP.
methodsEight patients with a clinically diagnosed PSP syndrome (PSPS) underwent antemortem 3 T magnetic resonance imaging (MRI) scanning and subsequent pathological diagnosis, confirming 6 PSP pathology and 2 multiple system atrophy (MSA) pathology cases. QSM analysis and Prussian blue staining were performed across subcortical regions.
resultsPSP cases showed higher susceptibility than age-matched controls in the pallidum, subthalamic nucleus, substantia nigra, and cerebellar dentate (false discovery rate [FDR]-corrected P < 0.05). PSP had higher susceptibility in the subthalamic nucleus and lower susceptibility in the putamen than the clinically atypical MSA (P = 0.08). Subcortical susceptibilities correlated with Prussian blue-stained areas (r = 0.63, P < 0.001).
conclusionsQSM could be a reliable measure to evaluate abnormal iron accumulation patterns in PSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.